Q3 EPS Estimates for AngioDynamics Cut by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Analysts at Zacks Research cut their Q3 2026 earnings estimates for AngioDynamics in a research report issued on Tuesday, March 25th. Zacks Research analyst D. Dey now expects that the medical instruments supplier will post earnings per share of ($0.05) for the quarter, down from their prior forecast of ($0.04). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.18) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.05) earnings per share.

Separately, HC Wainwright upped their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Price Performance

ANGO stock opened at $9.83 on Friday. AngioDynamics has a fifty-two week low of $5.47 and a fifty-two week high of $13.50. The stock has a market capitalization of $397.78 million, a PE ratio of -1.75 and a beta of 0.56. The company has a 50 day moving average price of $10.47 and a 200 day moving average price of $8.77.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its position in AngioDynamics by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 326,820 shares of the medical instruments supplier’s stock valued at $2,543,000 after buying an additional 11,599 shares in the last quarter. FMR LLC grew its holdings in shares of AngioDynamics by 105.0% in the third quarter. FMR LLC now owns 52,779 shares of the medical instruments supplier’s stock valued at $411,000 after acquiring an additional 27,031 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of AngioDynamics by 110.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock valued at $1,240,000 after purchasing an additional 83,622 shares during the last quarter. Walleye Capital LLC purchased a new position in AngioDynamics in the third quarter valued at about $546,000. Finally, Quarry LP grew its holdings in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 2,471 shares during the period. 89.43% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.40% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.